Tag: Pluristem Therapeutics

November 28, 2018

Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will...
October 16, 2018

U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

Pluristem Therapeutics (Nasdaq:PSTI;TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial a privately-held third-party sponsor...
September 25, 2018

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food...
August 8, 2018

Pluristem Initiates Two Pivotal Phase III Studies in Israel

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared...
July 9, 2018

Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 25, 2018

U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

Pluristem Therapeutics (Nasdaq:PSTI) a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA)...